[go: up one dir, main page]

CN102850319A - Preparation method of {5-[2-(4-n-octyl-phenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl} carbamic acid tert-butyl ester - Google Patents

Preparation method of {5-[2-(4-n-octyl-phenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl} carbamic acid tert-butyl ester Download PDF

Info

Publication number
CN102850319A
CN102850319A CN2011101748711A CN201110174871A CN102850319A CN 102850319 A CN102850319 A CN 102850319A CN 2011101748711 A CN2011101748711 A CN 2011101748711A CN 201110174871 A CN201110174871 A CN 201110174871A CN 102850319 A CN102850319 A CN 102850319A
Authority
CN
China
Prior art keywords
formula
compound
octyl
dimethyl
dioxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011101748711A
Other languages
Chinese (zh)
Inventor
孙宏斌
甄乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN2011101748711A priority Critical patent/CN102850319A/en
Publication of CN102850319A publication Critical patent/CN102850319A/en
Pending legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及芬戈莫德中间体的制备方法,具体涉及{5-[2-(4-正辛基苯基)乙基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯的制备方法,包括如下步骤:正辛基卤代烷制成的格氏试剂与4-卤代苯甲酸酯发生交叉偶联反应,生成的4-正辛基苯甲酸酯经还原生成4-正辛基苯甲醇,再经卤代反应制得4-正辛基苄基卤代物,卤代物与三苯基膦反应,生成(4-正辛基苄基)三苯基卤化鏻,该化合物与(5-甲酰基-2,2-二甲基-1,3-二氧六环-5-基)氨基甲酸叔丁酯发生维蒂希反应,生成{5-[2-(4-正辛基苯基)乙烯基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯,再经氢化还原制得标题化合物。The present invention relates to the preparation method of fingolimod intermediate, in particular to {5-[2-(4-n-octylphenyl)ethyl]-2,2-dimethyl-1,3-dioxane The preparation method of -5-base} tert-butyl carbamate comprises the steps of: the Grignard reagent made by n-octyl haloalkane and 4-halogenated benzoate undergo cross-coupling reaction, and the 4-n-octyl group generated Benzoic acid ester is reduced to generate 4-n-octylbenzyl alcohol, and then through halogenation reaction to obtain 4-n-octylbenzyl halide, which reacts with triphenylphosphine to generate (4-n-octylbenzyl ) triphenylphosphonium halide, which reacts with (5-formyl-2,2-dimethyl-1,3-dioxane-5-yl)carbamate tert-butyl ester to produce { 5-[2-(4-n-octylphenyl)ethenyl]-2,2-dimethyl-1,3-dioxane-5-yl}carbamate tert-butyl ester, then hydrogenation reduction The title compound was obtained.

Description

一种制备{5-[2-(4-正辛基苯基)乙基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯的方法A method for preparing tert-butyl {5-[2-(4-n-octylphenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl}carbamate

技术领域 technical field

本发明涉及制药领域,具体涉及{5-[2-(4-正辛基苯基)乙基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯的制备方法。  The invention relates to the field of pharmacy, in particular to {5-[2-(4-n-octylphenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl}carbamic acid Preparation method of tert-butyl ester. the

背景技术 Background technique

芬戈莫德(Fingolimod),商品名为Gilenya,结构为2-氨基-2-[2-(4-正辛基苯基)乙基]-1,3-丙二醇。2010年9月22日,美国FDA批准使用芬戈莫德作为复发型多发性硬化症的一线用药,成为首个获批的口服给药治疗该疾病的药物。目前,该药已经获准在美国、加拿大、欧洲、俄罗斯、澳大利亚上市。  Fingolimod, whose trade name is Gilenya, has the structure of 2-amino-2-[2-(4-n-octylphenyl)ethyl]-1,3-propanediol. On September 22, 2010, the US FDA approved the use of fingolimod as a first-line drug for relapsing multiple sclerosis, becoming the first approved oral drug for the treatment of the disease. Currently, the drug has been approved for marketing in the United States, Canada, Europe, Russia, and Australia. the

如式I所示的{5-[2-(4-正辛基苯基)乙基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯是合成芬戈莫德及其衍生物的重要中间体。目前,只有2篇文献报道了式I化合物的制备方法。Kim等(Synthesis,2006,5,753-755)报道了一种式I化合物的制备方法,采用4-正辛基碘化苯为原料,其价格较高,且不易获得;该方法还使用成本较高的叠氮化物,且具有危险性;此外,所采用的钯催化交叉偶联反应的生产成本高,不适宜大规模生产。Balasubramaniam等(Synlett,2007,18,2841-2846)所报道的式I化合物的制备方法,其步骤繁琐,且采用剧毒的四氯化碳作溶剂,总收率不高,因而也不适于工业化生产。  {5-[2-(4-n-octylphenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl}carbamic acid tert-butyl as shown in formula I Esters are important intermediates in the synthesis of fingolimod and its derivatives. At present, there are only 2 documents reporting the preparation method of the compound of formula I. Kim et al. (Synthesis, 2006, 5, 753-755) reported a preparation method of a compound of formula I, using 4-n-octyl iodide benzene as a raw material, which has a higher price and is not easy to obtain; the method also uses cost Higher azide, and dangerous; In addition, the production cost of the palladium-catalyzed cross-coupling reaction adopted is high, and is not suitable for large-scale production. (Synlett, 2007, 18, 2841-2846) reported the preparation method of formula I compound, its step is loaded down with trivial details, and adopts highly toxic carbon tetrachloride to make solvent, and total yield is not high, thus also not suitable for industrialization Production. the

Figure BSA00000525402200011
Figure BSA00000525402200011

发明内容 Contents of the invention

本发明所要解决的技术问题是要克服上述{5-[2-(4-正辛基苯基)乙基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯(式I化合物)制备方法的不足,提供一种成本低、操作方便、收率高且绿色环保的可工业化实施的制备方法。  The technical problem to be solved by this invention is to overcome the above-mentioned {5-[2-(4-n-octylphenyl) ethyl]-2,2-dimethyl-1,3-dioxane-5-yl } The deficiencies in the preparation method of tert-butyl carbamate (compound of formula I) provide a preparation method that is low in cost, easy to operate, high in yield and environmentally friendly and can be implemented industrially. the

本发明提供的式I化合物的制备方法,如下式所示:  The preparation method of the compound of formula I provided by the invention is shown in the following formula:

Figure BSA00000525402200021
Figure BSA00000525402200021

本发明提供的式I化合物的制备方法,具体包括以下步骤:  The preparation method of the formula I compound provided by the invention specifically comprises the following steps:

(1)将1-卤代正辛烷(式II化合物)  (1) 1-halogenated n-octane (compound of formula II)

Figure BSA00000525402200022
Figure BSA00000525402200022

先制成格氏试剂,再与4-卤代苯甲酸酯(式III化合物)  First make Grignard reagent, and then with 4-halogenated benzoic acid ester (compound of formula III)

Figure BSA00000525402200023
Figure BSA00000525402200023

发生交叉偶联反应,生成4-正辛基苯甲酸酯(式IV化合物)  A cross-coupling reaction occurs to generate 4-n-octylbenzoic acid ester (compound of formula IV)

Figure BSA00000525402200031
Figure BSA00000525402200031

在式II中,X为卤素,优选氯或溴;  In formula II, X is halogen, preferably chlorine or bromine;

在式III中,R为C1~10的烷基,优选甲基或乙基;Y为卤素,优选氯或溴;  In formula III, R is an alkyl group of C1~10, preferably methyl or ethyl; Y is a halogen, preferably chlorine or bromine;

在式IV中,R的定义同上述式III中的定义;  In formula IV, the definition of R is the same as the definition in above-mentioned formula III;

(2)将式IV化合物还原生成4-正辛基苯甲醇(式V化合物)  (2) Formula IV compound is reduced to generate 4-n-octyl benzyl alcohol (formula V compound)

Figure BSA00000525402200032
Figure BSA00000525402200032

(3)将式V化合物进行卤代反应,生成4-正辛基苄基卤代物(式VI化合物)  (3) The compound of formula V is subjected to halogenation reaction to generate 4-n-octylbenzyl halide (compound of formula VI)

Figure BSA00000525402200033
Figure BSA00000525402200033

在式VI中,Z为卤素,优选氯或溴;  In formula VI, Z is halogen, preferably chlorine or bromine;

(4)将式VI化合物与三苯基膦反应,生成(4-正辛基苄基)三苯基卤化鏻(式VII化合物)  (4) react the compound of formula VI with triphenylphosphine to generate (4-n-octylbenzyl) triphenylphosphonium halide (compound of formula VII)

Figure BSA00000525402200034
Figure BSA00000525402200034

在式VII中,Z的定义同上述式VI中的定义;  In formula VII, the definition of Z is the same as the definition in the above-mentioned formula VI;

(5)将(5-甲酰基-2,2-二甲基-1,3-二氧六环-5-基)氨基甲酸叔丁酯(式VIII化合物)  (5) (5-formyl-2,2-dimethyl-1,3-dioxane-5-yl) tert-butyl carbamate (compound of formula VIII)

Figure BSA00000525402200035
Figure BSA00000525402200035

与式VII化合物在碱的作用下发生维蒂希(Wittig)反应,生成{5-[2-(4-正辛基苯基)乙烯基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯(式IX化合物)  Wittig (Wittig) reaction occurs with the compound of formula VII under the effect of base to generate {5-[2-(4-n-octylphenyl) vinyl]-2,2-dimethyl-1,3- Dioxane-5-yl}carbamate tert-butyl ester (compound of formula IX)

Figure BSA00000525402200036
Figure BSA00000525402200036

(6)将式IX化合物进行氢化还原,制得式I化合物  (6) The compound of formula IX is hydrogenated and reduced to obtain the compound of formula I

Figure BSA00000525402200041
Figure BSA00000525402200041

在上述步骤(1)中,将式II化合物先制成格氏试剂,再与4-卤代苯甲酸酯(式III化合物)进行交叉偶联反应制得4-正辛基苯甲酸酯(式IV化合物),具体制备方法参考专利文献US7026478。  In the above-mentioned step (1), the compound of formula II is first prepared as a Grignard reagent, and then cross-coupling with 4-halogenated benzoate (compound of formula III) to obtain 4-n-octyl benzoate (Compound of formula IV), the specific preparation method refers to the patent document US7026478. the

在上述步骤(2)中,将式IV化合物还原生成4-正辛基苯甲醇(式V化合物),该反应按本领域技术人员已知的常规方法进行,所采用的还原剂可以是四氢铝锂、硼氢化钠或硼氢化钾,优选硼氢化钠/氯化锂或硼氢化钾/氯化锂的还原体系。  In the above-mentioned step (2), the compound of formula IV is reduced to generate 4-n-octylbenzyl alcohol (compound of formula V), and the reaction is carried out by conventional methods known to those skilled in the art. Aluminum lithium, sodium borohydride or potassium borohydride, preferably a sodium borohydride/lithium chloride or potassium borohydride/lithium chloride reducing system. the

在上述步骤(3)中,将式V化合物进行卤代反应,生成4-正辛基苄基卤代物(式VI化合物),该反应按本领域技术人员已知的常规方法进行,所采用的卤化试剂可以是氯化亚砜、氯化氢、浓盐酸、溴化氢溶液、三溴化磷、五氯化磷或三苯基膦/四氯化碳。  In the above-mentioned step (3), the compound of formula V is subjected to a halogenation reaction to generate 4-n-octylbenzyl halide (compound of formula VI), and the reaction is carried out according to a conventional method known to those skilled in the art. The halogenating reagent can be thionyl chloride, hydrogen chloride, concentrated hydrochloric acid, hydrogen bromide solution, phosphorus tribromide, phosphorus pentachloride or triphenylphosphine/carbon tetrachloride. the

在上述步骤(4)中,将式VI化合物与三苯基膦反应,生成(4-正辛基苄基)三苯基卤化鏻(式VII化合物),该反应按本领域技术人员已知的常规方法进行,反应溶剂可以是甲苯、二氯甲烷、N,N-二甲基甲酰胺或四氢呋喃;反应温度可在30℃~各溶剂回流温度之间选择。  In the above-mentioned step (4), the compound of formula VI is reacted with triphenylphosphine to generate (4-n-octylbenzyl) triphenylphosphonium halide (compound of formula VII). The conventional method is used, and the reaction solvent can be toluene, dichloromethane, N, N-dimethylformamide or tetrahydrofuran; the reaction temperature can be selected between 30°C and the reflux temperature of each solvent. the

在上述步骤(5)中,将(5-甲酰基-2,2-二甲基-1,3-二氧六环-5-基)氨基甲酸叔丁酯(式VIII化合物)与式VII化合物在碱的作用下发生维蒂希(Wittig)反应,生成{5-[2-(4-正辛基苯基)乙烯基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯(式IX化合物),该反应按本领域技术人员已知的常规方法进行,式VII化合物与式VIII化合物的摩尔比优选1~1.5∶1;所采用的碱可以是氢化钠、叔丁醇钾、甲醇钠、乙醇钠、氢氧化钠、氢氧化钾、碳酸钾或三乙胺,优选甲醇钠、乙醇钠或氢氧化钠;式VII化合物与碱的摩尔比优选1∶1~3;所采用的溶剂可以是四氢呋喃、N,N-二甲基甲酰胺、二甲亚砜或二氯甲烷;反应温度可在-78℃~各溶剂回流温度之间选择;式VIII化合物可参照文献方法(Synthesis,2006,5,753-755)制备。  In the above step (5), (5-formyl-2,2-dimethyl-1,3-dioxane-5-yl) tert-butyl carbamate (compound of formula VIII) and compound of formula VII A Wittig reaction occurs under the action of a base to generate {5-[2-(4-n-octylphenyl)vinyl]-2,2-dimethyl-1,3-dioxane -5-base} carbamic acid tert-butyl ester (formula IX compound), this reaction is carried out by conventional methods known to those skilled in the art, and the mol ratio of formula VII compound and formula VIII compound is preferably 1~1.5: 1; Adopted The base can be sodium hydride, potassium tert-butoxide, sodium methoxide, sodium ethoxide, sodium hydroxide, potassium hydroxide, potassium carbonate or triethylamine, preferably sodium methoxide, sodium ethoxide or sodium hydroxide; The ratio is preferably 1:1~3; the solvent used can be tetrahydrofuran, N,N-dimethylformamide, dimethyl sulfoxide or methylene chloride; the reaction temperature can be selected between -78 ° C and the reflux temperature of each solvent The compound of formula VIII can be prepared with reference to the literature method (Synthesis, 2006, 5, 753-755). the

在上述步骤(6)中,将式IX化合物进行氢化还原,制得式I化合物,该反应按本领域技术人员已知的常规方法进行,所采用的催化剂为钯碳、雷尼镍或铂类催化剂,优选钯碳;反应溶剂为水、乙醇、甲醇、乙酸、乙酸乙酯、甲苯、四氢呋喃或N,N-二甲基甲酰胺,优选甲苯、四氢呋喃、甲醇或乙醇;反应温度可在室温至各溶剂回流温度之间选择。  In the above step (6), the compound of formula IX is subjected to hydrogenation reduction to obtain the compound of formula I. The reaction is carried out by conventional methods known to those skilled in the art, and the catalyst used is palladium carbon, Raney nickel or platinum Catalyst, preferred palladium carbon; Reaction solvent is water, ethanol, methyl alcohol, acetic acid, ethyl acetate, toluene, tetrahydrofuran or N, N-dimethylformamide, preferred toluene, tetrahydrofuran, methyl alcohol or ethanol; Reaction temperature can be at room temperature to Choose between the reflux temperature of each solvent. the

本发明的显著成效在于,本发明所提供的制备方法可以方便地用于制备{5-[2-(4-正辛基苯基)乙基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯,进而可以方便地制备药物芬戈莫德。与现有的文献方法相比,本发明所提供的制备方法具有以下优势:原料廉价易得、总收率高、生产成本低、反应条件温和且后处理方便,因而可进行工业化实施。  The remarkable effect of the present invention is that the preparation method provided by the present invention can be conveniently used to prepare {5-[2-(4-n-octylphenyl)ethyl]-2,2-dimethyl-1,3 -Dioxane-5-yl}carbamate tert-butyl ester, and then the drug fingolimod can be prepared conveniently. Compared with the existing literature methods, the preparation method provided by the present invention has the following advantages: raw materials are cheap and easy to obtain, the total yield is high, the production cost is low, the reaction conditions are mild and the post-treatment is convenient, so it can be implemented industrially. the

具体实施方式 Detailed ways

以下通过实施例进一步描述本发明,但是,这些实施例仅是用于说明本发明,而不是对 本发明范围的限制。  The present invention is further described by the following examples, but these examples are only used to illustrate the present invention, rather than limiting the scope of the present invention. the

实施例1  Example 1

4-正辛基苯甲酸甲酯的合成  Synthesis of methyl 4-n-octylbenzoate

格氏试剂的制备:氮气保护下,向装有镁屑(1.728g,72.0mmol)与四氢呋喃(20mL)的密闭三颈瓶中,加入1,2-二溴乙烷(0.3mL,3.6mmol)进行引发。待引发开始后,将1-溴正辛烷(11.58g,60mmol)的四氢呋喃(100mL)溶液向反应瓶中逐滴加入,滴速控制在能够维持反应液微沸,室温剧烈搅拌约30分钟后,镁屑大量减少,冷至室温备用。  Preparation of Grignard reagent: under nitrogen protection, add 1,2-dibromoethane (0.3mL, 3.6mmol) to a closed three-necked flask containing magnesium chips (1.728g, 72.0mmol) and tetrahydrofuran (20mL) to initiate. After the initiation started, a solution of 1-bromo-n-octane (11.58g, 60mmol) in tetrahydrofuran (100mL) was added dropwise to the reaction flask, and the dropping rate was controlled to maintain the slight boiling of the reaction solution. After stirring vigorously at room temperature for about 30 minutes, , the magnesium chips are greatly reduced, and cooled to room temperature for later use. the

交叉偶联反应:在格氏试剂制备的同时,将对氯苯甲酸甲酯(8.5295g,50mmol)、乙酰丙酮铁(950mg,2.69mmol,5.4%)溶于四氢呋喃(300mL)与N-甲基吡咯烷酮(16mL)的混合溶剂中,在冰浴冷却下搅拌。氮气保护下,将已经冷至室温的上述格氏试剂于1分钟左右逐滴加入,冰浴冷却下继续搅拌30分钟后,再室温搅拌10分钟。将反应液倾入乙酸乙酯(200mL)中,用1M盐酸淬灭,分出有机相,水相再用乙酸乙酯萃取(50mL×3)。合并有机相,用饱和食盐水洗涤(50mL×3),无水硫酸钠干燥,减压浓缩得微黄色油状物11.02g,产率86.7%。1H NMR(300MHz,CDCl3):δ0.87(t,J=6.7Hz,3H),1.2-1.42(br d,J=9.5Hz,10H),1.62(t,2H,J=7.4Hz),2.68(t,J=7.7Hz,2H),3.91(s,3H),7.24(d,J=8.3Hz,2H),7.93(d,J=8.2Hz,2H).  Cross-coupling reaction: while Grignard reagent was being prepared, methyl p-chlorobenzoate (8.5295 g, 50 mmol), iron acetylacetonate (950 mg, 2.69 mmol, 5.4%) were dissolved in tetrahydrofuran (300 mL) and N-methyl In a mixed solvent of pyrrolidone (16 mL), the mixture was stirred under ice-cooling. Under the protection of nitrogen, the above-mentioned Grignard reagent that had been cooled to room temperature was added dropwise in about 1 minute, and the stirring was continued for 30 minutes under ice-cooling, and then stirred at room temperature for 10 minutes. The reaction solution was poured into ethyl acetate (200 mL), quenched with 1M hydrochloric acid, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated brine (50 mL×3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 11.02 g of a slightly yellow oil with a yield of 86.7%. 1 H NMR (300MHz, CDCl 3 ): δ0.87(t, J=6.7Hz, 3H), 1.2-1.42(br d, J=9.5Hz, 10H), 1.62(t, 2H, J=7.4Hz) , 2.68(t, J=7.7Hz, 2H), 3.91(s, 3H), 7.24(d, J=8.3Hz, 2H), 7.93(d, J=8.2Hz, 2H).

实施例2  Example 2

4-正辛基苯甲醇的合成  Synthesis of 4-n-octylbenzyl alcohol

将4-正辛基苯甲酸甲酯(3.1g,12.5mmol)、无水氯化锂(2.1g,50mmol)、硼氢化钠(1.89g,50mmol)加入到乙二醇二甲醚(80mL)中,回流反应6小时。反应液用1M盐酸淬灭,并调pH近中性,再用乙酸乙酯萃取,有机层分别用饱和碳酸氢钠溶液(25mL)和饱和食盐水(30mL×3)洗涤,无水硫酸钠干燥,减压浓缩得无色油状物2.62g,产率95%。1HNMR(300MHz,CDCl3):δ0.87(t,J=6.7Hz,3H),1.19-1.42(br d,J=8.4Hz,10H),1.58(t,J=7.4Hz,2H),1.87(s,1H),2.59(t,J=7.7Hz,2H),4.61(s,2H),7.15(d,J=7.8Hz,2H),7.25(d,J=7.9Hz,2H).  Add methyl 4-n-octylbenzoate (3.1 g, 12.5 mmol), anhydrous lithium chloride (2.1 g, 50 mmol), sodium borohydride (1.89 g, 50 mmol) to ethylene glycol dimethyl ether (80 mL) In, reflux reaction for 6 hours. The reaction solution was quenched with 1M hydrochloric acid, adjusted to near neutral pH, and then extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate solution (25mL) and saturated brine (30mL×3), and dried over anhydrous sodium sulfate. , and concentrated under reduced pressure to obtain 2.62 g of a colorless oil, with a yield of 95%. 1 HNMR (300MHz, CDCl 3 ): δ0.87(t, J=6.7Hz, 3H), 1.19-1.42(br d, J=8.4Hz, 10H), 1.58(t, J=7.4Hz, 2H), 1.87(s, 1H), 2.59(t, J=7.7Hz, 2H), 4.61(s, 2H), 7.15(d, J=7.8Hz, 2H), 7.25(d, J=7.9Hz, 2H).

实施例3  Example 3

4-正辛基溴苄的合成  Synthesis of 4-n-octylbenzyl bromide

将4-正辛基苯甲醇(2.2g,10mmol)溶于二氯甲烷(40mL)中,滴加三溴化磷(0.9g,3.33mmol),室温搅拌30分钟后,用冰水淬灭反应,再用二氯甲烷萃取,有机层依次用饱和碳酸氢钠溶液(20mL×3)和饱和食盐水(30mL×3)洗涤,无水硫酸钠干燥,加压浓缩得淡黄色油状物2.60g,产率92%。1H NMR(300MHz,CDCl3):δ0.87(t,J=6.5Hz,3H),1.19-1.42(br d,J=9.5Hz,10H),1.59(t,J=7.4Hz,2H),2.59(t,J=7.7Hz,2H),4.49(s,2H),7.14(d,J=8.0Hz,2H),7.29(d,J=8.1Hz,2H).  Dissolve 4-n-octylbenzyl alcohol (2.2g, 10mmol) in dichloromethane (40mL), add phosphorus tribromide (0.9g, 3.33mmol) dropwise, stir at room temperature for 30 minutes, then quench the reaction with ice water , and then extracted with dichloromethane, the organic layer was washed successively with saturated sodium bicarbonate solution (20mL×3) and saturated brine (30mL×3), dried over anhydrous sodium sulfate, and concentrated under pressure to obtain 2.60g of light yellow oil, Yield 92%. 1 H NMR (300MHz, CDCl 3 ): δ0.87(t, J=6.5Hz, 3H), 1.19-1.42(br d, J=9.5Hz, 10H), 1.59(t, J=7.4Hz, 2H) , 2.59(t, J=7.7Hz, 2H), 4.49(s, 2H), 7.14(d, J=8.0Hz, 2H), 7.29(d, J=8.1Hz, 2H).

实施例4  Example 4

(4-正辛基苄基)三苯基溴化鏻的合成  Synthesis of (4-n-octylbenzyl)triphenylphosphonium bromide

将4-正辛基溴苄(2.55g,9mmol)和三苯基膦(2.60g,10mmol)溶于甲苯(50mL)中,于100℃加热反应5小时,析出白色固体,过滤,白色固体用甲苯洗涤后干燥,得白色粉末状固体4.8g,产率98%。1H NMR(300MHz,CDCl3):δ0.87(t,J=6.5Hz,3H),1.26(s,10H),1.52(s,2H),2.19(s,1H),2.50(t,J=7.4Hz,2H),5.22(d,J=14.0Hz,2H),6.94(d,J=8.4Hz,2H),6.96(d,J=8.6Hz,2H),7.51-7.82(m,15H).  Dissolve 4-n-octylbenzyl bromide (2.55g, 9mmol) and triphenylphosphine (2.60g, 10mmol) in toluene (50mL), heat and react at 100°C for 5 hours, and a white solid precipitates, which is filtered and used for After washing with toluene and drying, 4.8 g of white powdery solid was obtained with a yield of 98%. 1 H NMR (300MHz, CDCl 3 ): δ0.87(t, J=6.5Hz, 3H), 1.26(s, 10H), 1.52(s, 2H), 2.19(s, 1H), 2.50(t, J =7.4Hz, 2H), 5.22(d, J=14.0Hz, 2H), 6.94(d, J=8.4Hz, 2H), 6.96(d, J=8.6Hz, 2H), 7.51-7.82(m, 15H ).

实施例5  Example 5

{5-[2-(4-正辛基苯基)乙烯基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯的合成  Synthesis of tert-butyl {5-[2-(4-n-octylphenyl)vinyl]-2,2-dimethyl-1,3-dioxane-5-yl}carbamate

将(5-甲酰基-2,2-二甲基-1,3-二氧六环-5-基)氨基甲酸叔丁酯(0.227g,0.875mmol)、(4-正辛基苄基)三苯基溴化鏻(0.519g,0.955mmol)溶于二氯甲烷(15mL)中,室温下滴入氢氧化钠溶液(3.75M,0.64mL),剧烈搅拌12小时后,加入饱和食盐水(15mL),分出有机层,水层用二氯甲烷(15mL×3)萃取。合并有机层,依次用饱和氯化铵溶液(20mL×3)和饱和食盐水(30mL×3)洗涤,无水硫酸钠干燥,减压浓缩得粗产品。经柱层析(洗脱剂为石油醚∶乙酸乙酯=30∶1)纯化得略带紫色的透明粘稠状物质0.35g,产率90%(反式∶顺式=1∶5)。顺式异构体:1H NMR(300MHz,CDCl3):δ0.87(t,J=6.7Hz,3H),1.28(m,10H),1.38(s,9H),1.44(s,3H),1.46(s,3H),1.59(m,2H),2.45(t,J=7.7Hz,2H),3.75(d,J=11.7Hz,2H),3.89(d,J=11.0Hz,2H),5.18(br s,1H),5.58(d,J=12.6Hz,1H),6.66(d,J=12.6Hz,1H),7.10(d,J=8.0Hz,2H),7.15(d,J=8.0Hz,2H);反式异构体:1H NMR(300MHz,CDCl3):δ0.87(t,J=6.7Hz,3H),1.28(m,10H),1.38(s,9H),1.44(s,3H),1.46(s,3H),1.59(m,2H),2.45(t,J=7.7Hz,2H),3.75(d,J=11.7Hz,2H),3.89(d,J=11.0Hz,2H),5.18(br s,1H),6.16(d,J=17.4Hz,1H),6.50(d,J=17.4Hz,1H),7.27(d,J=6.6Hz,4H).  (5-formyl-2,2-dimethyl-1,3-dioxan-5-yl)carbamate tert-butyl ester (0.227g, 0.875mmol), (4-n-octylbenzyl) Triphenylphosphonium bromide (0.519g, 0.955mmol) was dissolved in dichloromethane (15mL), sodium hydroxide solution (3.75M, 0.64mL) was added dropwise at room temperature, after vigorous stirring for 12 hours, saturated saline ( 15 mL), the organic layer was separated, and the aqueous layer was extracted with dichloromethane (15 mL×3). The organic layers were combined, washed successively with saturated ammonium chloride solution (20 mL×3) and saturated brine (30 mL×3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product. Purified by column chromatography (petroleum ether: ethyl acetate = 30:1) to obtain 0.35 g of a purplish transparent viscous substance with a yield of 90% (trans:cis = 1:5). Cis isomer: 1 H NMR (300MHz, CDCl 3 ): δ0.87(t, J=6.7Hz, 3H), 1.28(m, 10H), 1.38(s, 9H), 1.44(s, 3H) , 1.46(s, 3H), 1.59(m, 2H), 2.45(t, J=7.7Hz, 2H), 3.75(d, J=11.7Hz, 2H), 3.89(d, J=11.0Hz, 2H) , 5.18(br s, 1H), 5.58(d, J=12.6Hz, 1H), 6.66(d, J=12.6Hz, 1H), 7.10(d, J=8.0Hz, 2H), 7.15(d, J =8.0Hz, 2H); trans isomer: 1 H NMR (300MHz, CDCl 3 ): δ0.87(t, J=6.7Hz, 3H), 1.28(m, 10H), 1.38(s, 9H) , 1.44(s, 3H), 1.46(s, 3H), 1.59(m, 2H), 2.45(t, J=7.7Hz, 2H), 3.75(d, J=11.7Hz, 2H), 3.89(d, J=11.0Hz, 2H), 5.18(br s, 1H), 6.16(d, J=17.4Hz, 1H), 6.50(d, J=17.4Hz, 1H), 7.27(d, J=6.6Hz, 4H ).

实施例6  Example 6

{5-[2-(4-正辛基苯基)乙基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯的合成  Synthesis of tert-butyl {5-[2-(4-n-octylphenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl}carbamate

将{5-[2-(4-正辛基苯基)乙烯基]-2,2-二甲基-1,3-二氧六环-5-基}氨基甲酸叔丁酯(220mg,0.5mmol)溶于四氢呋喃(10mL)中,加入5%钯碳(30mg),进行常压催化氢化反应,室温反应12小时后,用硅藻土将钯碳滤除,滤液减压浓缩后得白色固体220mg,产率99%。M.p.:60-61℃(文献值:63℃)。1H NMR(300MHz,CDCl3):δ0.87(t,J=6.7Hz,3H),1.28(m,10H),1.41(s,3H),1.43(s,3H),1.47(s,9H),1.58(m,2H),1.97(m,2H),2.50-2.58(m,4H),3.67(d,J=12.0Hz,2H),3.90(d,J=12.0Hz,2H),4.97(br s,1H),7.08(s,4H).  Tert-butyl {5-[2-(4-n-octylphenyl)vinyl]-2,2-dimethyl-1,3-dioxane-5-yl}carbamate (220mg, 0.5 mmol) was dissolved in tetrahydrofuran (10mL), and 5% palladium carbon (30mg) was added to carry out atmospheric pressure catalytic hydrogenation reaction. After 12 hours of reaction at room temperature, the palladium carbon was filtered off with diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain a white solid 220 mg, 99% yield. Mp: 60-61°C (literature value: 63°C). 1 H NMR (300MHz, CDCl 3 ): δ0.87(t, J=6.7Hz, 3H), 1.28(m, 10H), 1.41(s, 3H), 1.43(s, 3H), 1.47(s, 9H ), 1.58(m, 2H), 1.97(m, 2H), 2.50-2.58(m, 4H), 3.67(d, J=12.0Hz, 2H), 3.90(d, J=12.0Hz, 2H), 4.97 (br s, 1H), 7.08(s, 4H).

Claims (6)

1. the method for { 5-[2-(4-n-octyl phenyl) ethyl]-2, the 2-dimethyl-1,3-dioxane-5-yl } t-butyl carbamate shown in the preparation formula I,
Figure FSA00000525402100011
The method may further comprise the steps:
(1) with the 1-halo octane shown in the formula II
Figure FSA00000525402100012
Make first Grignard reagent, again with the 4-halogenated benzoic acid ester shown in the formula III
Figure FSA00000525402100013
Cross-coupling reaction occurs, the 4-n-octyl manthanoate shown in the production IV
Figure FSA00000525402100014
Wherein, the X among the formula II is halogen, preferred chlorine or bromine; R in the formula III is the alkyl of C1~10, preferable methyl or ethyl; Y is halogen, preferred chlorine or bromine; The definition of R among the formula IV is with the definition in the above-mentioned formula III;
(2) with the 4-n-octyl methyl alcohol shown in the formula IV compound reduction production V
(3) formula V compound is carried out halogenating reaction, the 4-n-octyl benzyl halides shown in the production VI
Figure FSA00000525402100016
Wherein, the Z among the formula VI is halogen, preferred chlorine or bromine;
(4) with formula VI compound and triphenylphosphine reaction, (4-n-octyl benzyl) the triphenyl phosphonium halide shown in the production VII
Figure FSA00000525402100021
Wherein, the definition of the Z among the formula VII is with the definition among the above-mentioned formula VI;
(5) with (5-formyl radical-2, the 2-dimethyl-1,3-dioxane-5-yl) t-butyl carbamate shown in the formula VIII
Figure FSA00000525402100022
Wittig (Wittig) reaction occurs under the effect of alkali with formula VII compound, shown in the production IX 5-[2-(4-n-octyl phenyl) vinyl] and-2,2-dimethyl-1,3-dioxane-5-yl } t-butyl carbamate
Figure FSA00000525402100023
(6) formula IX compound is carried out the catalytic hydrogenation reduction, make formula I compound
2. preparation method according to claim 1, it is characterized in that, in the step (2) of claim 1, the reduction of formula IV compound is generated 4-n-octyl methyl alcohol, the reductive agent that adopts can be Lithium Aluminium Hydride, sodium borohydride or POTASSIUM BOROHYDRIDE, the reduction system of preferred sodium borohydride/lithium chloride or POTASSIUM BOROHYDRIDE/lithium chloride.
3. preparation method according to claim 1, it is characterized in that, in the step (3) of claim 1,4-n-octyl methyl alcohol is carried out halogenating reaction, generate 4-n-octyl benzyl halides, the halide reagent that adopts can be sulfur oxychloride, hydrogenchloride, concentrated hydrochloric acid, hydrogen bromide solution, phosphorus tribromide, phosphorus pentachloride or triphenylphosphine/tetracol phenixin.
4. preparation method according to claim 1, it is characterized in that, in the step (5) of claim 1, with (5-formyl radical-2,2-dimethyl-1,3-dioxane-5-yl) Wittig reaction occurs, the mol ratio preferred 1~1.5: 1 of formula VII compound and formula VIII compound with formula VII compound in t-butyl carbamate (VIII compound) under the effect of alkali; The alkali that adopts can be sodium hydride, potassium tert.-butoxide, sodium methylate, sodium ethylate, sodium hydroxide, potassium hydroxide, salt of wormwood or triethylamine, particular methanol sodium, sodium ethylate or sodium hydroxide; The mol ratio of formula VII compound and alkali preferred 1: 1~3; The solvent that adopts can be tetrahydrofuran (THF), DMF, methyl-sulphoxide or methylene dichloride; Temperature of reaction can be selected between-78 ℃~each solvent refluxing temperature.
5. preparation method according to claim 1 is characterized in that, the catalyzer that adopts in the step (6) of claim 1 is palladium carbon, Raney's nickel or platinum class catalyzer, preferred palladium carbon; Reaction solvent is water, ethanol, methyl alcohol, acetic acid, ethyl acetate, toluene, tetrahydrofuran (THF) or DMF, preferred toluene, tetrahydrofuran (THF), methyl alcohol or ethanol.
6. { 5-[2-(4-n-octyl phenyl) vinyl]-2,2-dimethyl-1,3-dioxane-5-yl } t-butyl carbamate shown in the formula IX
Figure FSA00000525402100031
Wherein, formula IX compound comprises the cis-trans-isomer of alkene.
CN2011101748711A 2011-06-27 2011-06-27 Preparation method of {5-[2-(4-n-octyl-phenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl} carbamic acid tert-butyl ester Pending CN102850319A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011101748711A CN102850319A (en) 2011-06-27 2011-06-27 Preparation method of {5-[2-(4-n-octyl-phenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl} carbamic acid tert-butyl ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101748711A CN102850319A (en) 2011-06-27 2011-06-27 Preparation method of {5-[2-(4-n-octyl-phenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl} carbamic acid tert-butyl ester

Publications (1)

Publication Number Publication Date
CN102850319A true CN102850319A (en) 2013-01-02

Family

ID=47397351

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011101748711A Pending CN102850319A (en) 2011-06-27 2011-06-27 Preparation method of {5-[2-(4-n-octyl-phenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl} carbamic acid tert-butyl ester

Country Status (1)

Country Link
CN (1) CN102850319A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145689A (en) * 2013-01-24 2013-06-12 华东师范大学 Method for combining Fingolimod intermediate
CN103275123A (en) * 2013-05-23 2013-09-04 浙江肯特化工有限公司 Preparation method of triphenylmethylphosphonium chloride

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613622A (en) * 1983-09-09 1986-09-23 Henkel Kommanditgesellschaft Auf Aktien Sebosuppressive preparations containing benzyl alcohol derivatives
EP0225602A2 (en) * 1985-12-06 1987-06-16 Ciba-Geigy Ag Alpha-hydroxythio ethers
CN1266844A (en) * 1999-03-11 2000-09-20 杭州中美华东制药有限公司 Process for preparing alkylphenylethyl aminopropanediol and intermediate obtained therein
CN1814583A (en) * 2006-03-01 2006-08-09 徐州师范大学 Method for preparing 2-P-octyl-phenenl-2-amino-propanediol hydrochloride
WO2011009634A2 (en) * 2009-07-24 2011-01-27 Ratiopharm Gmbh Process for producing fingolimod salts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613622A (en) * 1983-09-09 1986-09-23 Henkel Kommanditgesellschaft Auf Aktien Sebosuppressive preparations containing benzyl alcohol derivatives
EP0225602A2 (en) * 1985-12-06 1987-06-16 Ciba-Geigy Ag Alpha-hydroxythio ethers
CN1266844A (en) * 1999-03-11 2000-09-20 杭州中美华东制药有限公司 Process for preparing alkylphenylethyl aminopropanediol and intermediate obtained therein
CN1814583A (en) * 2006-03-01 2006-08-09 徐州师范大学 Method for preparing 2-P-octyl-phenenl-2-amino-propanediol hydrochloride
WO2011009634A2 (en) * 2009-07-24 2011-01-27 Ratiopharm Gmbh Process for producing fingolimod salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIVARAMAN BALASUBRAMANIAM ET AL.,: "Weinreb Amide Based New Synthetic Equivalents for Convenient Access to Immunosuppressive Agent FTY720 and Ananlogues", 《SYNLETT》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145689A (en) * 2013-01-24 2013-06-12 华东师范大学 Method for combining Fingolimod intermediate
CN103145689B (en) * 2013-01-24 2014-07-16 华东师范大学 Method for combining Fingolimod intermediate
CN103275123A (en) * 2013-05-23 2013-09-04 浙江肯特化工有限公司 Preparation method of triphenylmethylphosphonium chloride
CN103275123B (en) * 2013-05-23 2016-07-06 肯特催化材料股份有限公司 A kind of preparation method of trityl group chlorination

Similar Documents

Publication Publication Date Title
CN103384663B (en) For the preparation of the synthesis of the intermediate of bent of Ansai and derivative thereof
CN102046576B (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
CN109776422B (en) Chiral 1, 3-diaryl imidazole salt carbene precursor, synthesis method thereof, metal salt compound and application
CN101279899A (en) Preparation method of 2-[2-(3-methoxyphenyl)ethyl]phenol
CN113185404B (en) 1, 2-biaxial chiral biaryl compound and preparation method and application thereof
TWI582098B (en) Organoboron compound and method for manufacturing the same
CN111646990B (en) A kind of preparation method of 3,4-bridged ring indole compound and the synthetic method of Rucaparib
CN103224479A (en) Synthetic method of 2-arylbenzofuran compounds
CN102391220A (en) Tricyclic ethanol compound, as well as preparation method and usages thereof
CN108558635B (en) Preparation method of 3-arylpropynoic acids and 3-arylpropynoic acid ester compounds
CN102850319A (en) Preparation method of {5-[2-(4-n-octyl-phenyl)ethyl]-2,2-dimethyl-1,3-dioxane-5-yl} carbamic acid tert-butyl ester
CN104370976A (en) Oxygen-containing substituent ferrocene oxazoline-phosphine ligand, as well as preparation method and application thereof in asymmetric cycloaddition reaction
CN112851608B (en) A kind of catalytic oxidation synthesis method of 2-diarylmethylbenzofuran compounds
CN112812033B (en) Novel synthesis method of oseltamivir
CN110845294B (en) Synthesis method of 1, 1-dihalogen-1-butene-3-alkyne compound
CN107021883B (en) Synthetic method and application of polysubstituted biphenyl halide liquid crystal intermediate
JP2009235061A (en) Method for producing dialcohol, method for producing allyl halide compound and allyl chloride compound
US9272966B2 (en) Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane
CN112778267A (en) Thiophene-3 (2H) -ketone compound and synthetic method thereof
CN107082763A (en) A kind of method for synthesizing indazole ketone compounds
CN114249679B (en) A method for preparing α,α-gedifluorocarbonyl compounds
CN114907266B (en) A kind of preparation method of dihydropyrazole compounds
CN106831522B (en) Lactam compound and preparation method thereof
CN116239562A (en) A kind of method taking benzofuranone as raw material to synthesize doxepin hydrochloride
CN113980055B (en) Cyclic phosphonamide derivative with biaryl framework, synthesis method and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130102